#5946 MULTICENTER STUDY EVALUATING THE FREQUENCY OF ADVERSE EVENTS ASSOCIATED WITH THE SARS-COV2 VACCINATION AMONG PATIENTS WITH GLOMERULAR DISEASES

Development of SARS-CoV-2 vaccination has altered the natural course of the related infection and the pandemic. The present study aims to explore the frequency of adverse events in patients with glomerular diseases (GD).

Patients with biopsy-broven GD, who received at least one dose of the vaccine against SARS-CoV-2 were studied retrospectively. Patients who ended up in ESKD prior to vaccination were excluded. We recorded demographics, histopathological diagnosis, past medical history, immunosuppressive regimens which were given at diagnosis and thereafter, outcome of the GD and adverse events associated with the vaccine, both systemic and local. We also estimated the rate of GD relapse post vaccination in patients who were in remission of the primary diseases compared with patients who decided not to receive the vaccine.

To date 280 patients with GD have been included in the study with a mean age of 47,6 (±17,8) years, of whom 111 (39,6%) are males. Patients received in total 3,0 (±0,9) vaccine doses with the mean time from the diagnostic kidney biopsy to the 1^st dose of being 76,5 (±61,5) months. 47,1% of the patients were on immunosuppressive therapy at the time of vaccination. 27,1% of the patients reported systemic side effects (fever, arthralgias, myalgias) and 50,7% reported local side effects (pain, swelling, itching, edema). Renal function and 24-hour proteinuria remained stable after vaccination. Among patients who were in remission of the GD at the time of vaccination 19 (8,2%) patients experienced a relapse of the primary disease after vaccination, versus 5% of patients not vaccinated (p = 0,99).

According to our findings the vaccine against SARS-CoV-2 appears safe for patients with GD with no significant impact in renal function or the probability for relapse.